OBJECTIVE: To assess whether supplementation with Coenzyme Q10 (CoQ10) during pregnancy reduces the risk of pre-eclampsia. METHODS:Women at increased risk of pre-eclampsia were enrolled in a randomized, double-blind, placebo-controlled trial. Women were assigned to receive 200 mg of CoQ10 or placebo daily from 20 weeks of pregnancy until delivery. The primary outcome was rate of pre-eclampsia. Statistical analyses were by intention-to-treat. RESULTS: Of the 235 women enrolled in the trial, 118 were randomized to receiveCoQ10 and 117 received a placebo. A total of 197 (83.8%) women were followed-up. The overall rate of pre-eclampsia was 20% (n=47). Thirty women (25.6%) in the placebo group developed pre-eclampsia compared with 17 women (14.4%) in the CoQ10 group, and this reduction was significant (P=0.035) (relative risk [RR] 0.56; 95% confidence interval [CI], 0.33-0.96). CONCLUSION: Supplementation with CoQ10 reduces the risk of developing pre-eclampsia in women at risk for the condition.
RCT Entities:
OBJECTIVE: To assess whether supplementation with Coenzyme Q10 (CoQ10) during pregnancy reduces the risk of pre-eclampsia. METHODS:Women at increased risk of pre-eclampsia were enrolled in a randomized, double-blind, placebo-controlled trial. Women were assigned to receive 200 mg of CoQ10 or placebo daily from 20 weeks of pregnancy until delivery. The primary outcome was rate of pre-eclampsia. Statistical analyses were by intention-to-treat. RESULTS: Of the 235 women enrolled in the trial, 118 were randomized to receive CoQ10 and 117 received a placebo. A total of 197 (83.8%) women were followed-up. The overall rate of pre-eclampsia was 20% (n=47). Thirty women (25.6%) in the placebo group developed pre-eclampsia compared with 17 women (14.4%) in the CoQ10 group, and this reduction was significant (P=0.035) (relative risk [RR] 0.56; 95% confidence interval [CI], 0.33-0.96). CONCLUSION: Supplementation with CoQ10 reduces the risk of developing pre-eclampsia in women at risk for the condition.
Authors: Jennifer E Bruin; Amanda K Woynillowicz; Bart P Hettinga; Mark A Tarnopolsky; Katherine M Morrison; Hertzel C Gerstein; Alison C Holloway Journal: J Diabetes Date: 2012-09 Impact factor: 4.006
Authors: Juan Garrido-Maraver; Mario D Cordero; Manuel Oropesa-Ávila; Alejandro Fernández Vega; Mario de la Mata; Ana Delgado Pavón; Manuel de Miguel; Carmen Pérez Calero; Marina Villanueva Paz; David Cotán; José A Sánchez-Alcázar Journal: Mol Syndromol Date: 2014-07
Authors: Fernanda Regina Giachini; Carlos Galaviz-Hernandez; Alicia E Damiano; Marta Viana; Angela Cadavid; Patricia Asturizaga; Enrique Teran; Sonia Clapes; Martin Alcala; Julio Bueno; María Calderón-Domínguez; María P Ramos; Victor Vitorino Lima; Martha Sosa-Macias; Nora Martinez; James M Roberts; Carlos Escudero Journal: Curr Hypertens Rep Date: 2017-10-06 Impact factor: 5.369